Phase II Trouble

Phase II clinical trials are in trouble, says Pharmalot's Ed Silverman. According to a new study in Nature Reviews Drug Discovery, success rates for Phase II trials fell from 28 percent in 2006 and 2007 to 18 percent in 2008 and 2009. "The implication is that the overall attrition of late-stage drug development seems to be unsustainably high," Silverman says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.